Land: Irland
Språk: engelska
Källa: HPRA (Health Products Regulatory Authority)
TESTOSTERONE UNDECANOATE
Bayer Limited
G03BA; G03BA03
TESTOSTERONE UNDECANOATE
1000 milligram(s)
Solution for injection
Product subject to prescription which may not be renewed (A)
3-oxoandrosten (4) derivatives; testosterone
Marketed
2004-11-12
1 PACKAGE LEAFLET: INFORMATION FOR THE USER NEBIDO 1000 MG/4 ML, SOLUTION FOR INJECTION Testosterone undecanoate READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU ARE GIVEN THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Nebido is and what it is used for 2. What you need to know before you are given Nebido 3. How to use Nebido 4. Possible side effects 5. How to store Nebido 6. Contents of the pack and other information 1. WHAT NEBIDO IS AND WHAT IT IS USED FOR Nebido contains testosterone, a male hormone, as the active ingredient. Nebido is injected into a muscle in your body. There it can be stored and gradually released over a period of time. Nebido is used in adult men for testosterone replacement to treat various health problems caused by a lack of testosterone (male hypogonadism). These should be confirmed by two separate blood testosterone measurements and also include clinical symptoms such as: • impotence • infertility • low sex drive • tiredness • depressive moods • bone loss caused by low hormone levels 2. WHAT YOU NEED TO KNOW BEFORE YOU ARE GIVEN NEBIDO DO NOT USE NEBIDO - if you are allergic to testosterone undecanoate or any of the other ingredients of this medicine (listed in section 6) - if you have androgen-dependent cancer or suspected cancer of the prostate or of the breast - if you have or had a liver tumour Nebido IS NOT intended for use in women. WARNINGS AND PRECAUTIONS TALK TO YOUR DOCTOR before using Nebido if you have or have ever had: BP21055 REC17464 2 - epilepsy - heart, kidney or liver problems - migraine - temporary interruptions in your brea Läs hela dokumentet
Health Products Regulatory Authority 24 November 2022 CRN00CMQP Page 1 of 10 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Nebido 1000 mg/4 ml, solution for injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml solution for injection contains 250 mg testosterone undecanoate corresponding to 157.9 mg testosterone. Each ampoule / vial with 4 ml solution for injection contains 1000 mg testosterone undecanoate corresponding to 631.5 mg testosterone. Excipient with known effect: 2000 mg benzyl benzoate per ampoule / vial. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Solution for injection Clear, colorless to yellowish-brown oily solution 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Testosterone replacement therapy for male hypogonadism, when testosterone deficiency has been confirmed by clinical features and biochemical tests (see section 4.4). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION POSOLOGY One ampoule / vial of Nebido (corresponding to 1000 mg testosterone undecanoate) is injected every 10 to 14 weeks. Injections with this frequency are capable of maintaining sufficient testosterone levels and do not lead to accumulation. Start of treatment Serum testosterone levels should be measured before start and during initiation of treatment. Depending on serum testosterone levels and clinical symptoms, the first injection interval may be reduced to a minimum of 6 weeks as compared to the recommended range of 10 to 14 weeks for maintenance. With this loading dose, sufficient steady state testosterone levels may be achieved more rapidly. Maintenance and individualisation of treatment The injection interval should be within the recommended range of 10 to 14 weeks. Careful monitoring of serum testosterone levels is required during maintenance of treatment. It is advisable to measure testosterone serum levels regularly. Measurements should be performed at the end of an injection interval and clinical symptoms considered. These serum levels should be within the lower Läs hela dokumentet